Pneumonia is the most common disease and its had highest mortality rate. Viral is the most common cause of pneumonia. In viral cause group, Cytomegalovirus (CMV) is also the most common in immunocompromised patients. But using antiviral still had controversial in effectiveness and side effect in non immunocompromised cases. Objective: Initial comment on effectiveness and side effect of Ganciclovir on Cytomegalovirus pneumonia in non immunocompromised pediatric patients. Results: This study focuses on 61 cases of CMV pneumonia admitted to the Respiratory Department of NHP from 1/2010-12/2011. Of 61 CMV pneumonia cases: This disease mostly appeared in male 60.66 percent, median age 57 days (range 45 -85 days). Clinical symptoms when admitted were: the illness already had duration of greater than 7 days, mild fever, cough, difficulty breathing, anemia, hepatospleenomegaly, WBC increased especially lymphocyte fever, increased liver enzymes, and thrombocytosis. 100 percent patients were treated until PCR CMV negative. All 61 patients received Gancyclovir (dose: 5-10mg/kg/day). Hospitalization: 26,88:+ or - 12.46 days. Antiviral duration treatment: 12.60 + or - 4.54 days. Treatment result: Out of the 60 patients 61 went home in a good condition (98.36 percent), mortality:1/61 (1.64 percent). the authorsdidn't see any severe side effect during treatment. Conclusion: Ganciclovir were safe and effective in over 90 percent CMV pneumonia patients, as determined by negative PCR at the end of the therapy.
- Đăng nhập để gửi ý kiến